A rare cutaneous manifestation of immune checkpoint inhibitor therapy

被引:0
|
作者
Cherneskie Jr, John [1 ]
Tuan, Alyssa [1 ]
Corey, Zachary [1 ]
Polimera, Hyma [1 ]
机构
[1] Penn State Coll Med, Hershey, PA 17033 USA
来源
CLINICAL CASE REPORTS | 2023年 / 11卷 / 04期
关键词
Immune checkpoint inhibitor; leukoclastic vasculitis;
D O I
10.1002/ccr3.7151
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Leukocytoclastic vasculitis can be an uncommon and/or underreported adverse event of immune checkpoint inhibitor therapy, an established cancer treatment option. Differentiation among other cutaneous manifestations of adverse medication reactions-such as Stevens-Johnson syndrome, erythema multiforme, and drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome-is crucial for guiding management.
引用
收藏
页数:3
相关论文
共 50 条
  • [1] Myocarditis: A Rare Complication of Immune Checkpoint Inhibitor Therapy
    Nair, Devi Parvathy Jyothi Ramachandran
    Zachariah, Shilla
    Scollan, David
    Shaikh, Atif
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (05)
  • [2] Cutaneous toxicities in lung cancer patients on immune checkpoint inhibitor therapy
    Keiser, Monika
    Patel, Anisha B.
    Altan, Mehmet
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB75 - AB75
  • [3] Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy
    Keiser, Monika F.
    Patel, Anisha B.
    Altan, Mehmet
    CLINICAL LUNG CANCER, 2021, 22 (03) : 195 - +
  • [4] Atezolizumab induced de novo rupoid psoriasis: A rare cutaneous manifestation of immune checkpoint inhibitors
    Mohta, Alpana
    Arora, Aakanksha
    Jain, Suresh Kumar
    JOURNAL OF COSMETIC DERMATOLOGY, 2022, 21 (05) : 2005 - 2008
  • [5] Immune Checkpoint Inhibitor Therapy as a Novel and Effective Therapy for Aggressive Cutaneous Squamous Cell Carcinoma
    Beasley, G.
    Kurtz, J.
    Howard, J. H.
    Terando, A.
    Agnese, D.
    David, L.
    Olencki, T.
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 : S37 - S37
  • [6] Cutaneous toxicities in combination immune checkpoint inhibitor therapy for metastatic melanoma: Impact on therapy course
    Patel, Anisha B.
    Farooq, Sahira
    Welborn, Macartney E.
    Haydu, Lauren E.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB17 - AB17
  • [7] Immune Checkpoint Inhibitor Therapy Toxicities
    Jim, Heather S. L.
    Knoop, Hans
    Dicker, Adam P.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (01): : 87 - 87
  • [8] Response to treatment of cutaneous immune-related adverse events following immune checkpoint inhibitor therapy
    Reardon, R. M.
    Perlman, K. L.
    Asdourian, M.
    Shah, N.
    Jacoby, T.
    Thompson, L. L.
    Reynolds, K.
    Chen, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (05) : S87 - S87
  • [9] CUTANEOUS ADVERSE EVENTS OF IMMUNE CHECKPOINT INHIBITOR THERAPY: INCIDENCE AND TYPES OF REACTIVE DERMATOSES
    Le, Thomas
    Kaul, Subuhi
    Wongvibulsin, Shannon
    Cappelli, Laura
    Naidoo, Jarushka
    Semenov, Yevgeniy
    Kwatra, Shawn
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A509 - A510
  • [10] Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses
    Le, Thomas K.
    Kaul, Subuhi
    Cappelli, Laura C.
    Naidoo, Jarushka
    Semenov, Yevgeniy R.
    Kwatra, Shawn G.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) : 1691 - 1695